News
January 29, 2024 – Case Study
Implementation of INTERCEPT Fibrinogen Complex (IFC) at Stanford Hospital – Improves Wait Times and Reduces Wastage
January 10, 2024 – EAST 2024 Presentation
Fibrinogen Supplementation in Hemorrhagic Shock: Role of INTERCEPT Fibrinogen Complex
October 14-17, 2023 – AABB 2023 Posters
Improved Turnaround Times and Reduced Wastage with Implementation of INTERCEPT Fibrinogen Complex (Four Independent Posters)
October 16, 2023 – AABB 2023 Presentation
Expanding the Use of Pathogen Reduction for Improved Blood Safety and Availability
May 8, 2023 – SCA 2023 Presentation
INTERCEPT® Fibrinogen Complex in Cardiac Surgery: Experience at Stanford Hospital
February 2, 2023 – Case Study
Implementing the Use of INTERCEPT Fibrinogen Complex (IFC) in the Pediatric Setting – Valley Children’s Hospital
January 19, 2023 – EAST 2023 Presentation
INTERCEPT Fibrinogen Complex: Initial Trauma Experience at UF Health
November 30, 2022 – AABB Webinar
INTERCEPT Fibrinogen Complex: Implementation and Initial Experience at Stanford Hospital
October 7, 2022 – Case Study
Assessing Impact of INTERCEPT Fibrinogen Complex (IFC) on Wastage and Massive Transfusion Protocols (MTPs) – UF Health
September 15, 2022 – SABM 2022 Presentation
Implementing the Use of INTERCEPT Fibrinogen Complex (IFC) in the Pediatric Setting
April 28, 2022 – AABB Webinar
UF Health Shands’ Experience to Date with INTERCEPT Fibrinogen Complex (IFC)
April 28, 2022 – AABB Webinar
Postpartum Hemorrhage and Target-Directed MTP Lessons Learned about Fibrinogen Replacement
March 16, 2022 – Legislative Update
Cerus Encouraged by the NDAA FY2022 Consideration of PR Resuscitative Products for Clinical Guidelines to Treat Obstetric Hemorrhage
Sept 20, 2021 – Press Release
Cerus Corporation Announces INTERCEPT Fibrinogen Complex Customer Presentations at SABM Virtual Annual Meeting 2021
Aug 20, 2021 – Announcement
First Patient Treated with
INTERCEPT Fibrinogen Complex
Aug 10, 2021 – Press Release
Cerus Corporation Announces CMS Issuance of P-Codes for Hospital Outpatient Billing of INTERCEPT-Based Therapeutic Products
Aug 3, 2021 – Press Release
Cerus Corporation Announces CMS Has Granted New Technology Add-On Payment for INTERCEPT Fibrinogen Complex
Nov 30, 2020 – Press Release
Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Cryoprecipitation
Oct 31, 2020 – Press Release
Cerus Receives FDA Breakthrough Device Designation for Pathogen-Reduced Cryoprecipitate